Australian Trial Shows CBD Gel Reduces Seizures in Epileptic Kids

October 7, 2019 08:00:30

Epilepsy is one of those diseases there’s no coming back from. Once diagnosed, the best you can do is find suitable ways to cope with it. It’s even more challenging if your little one is afflicted, and it can have a tremendous impact on the families affected. While there is currently no cure for epilepsy, there’s a host of anti-seizure meds that can reduce the frequency of the seizures and give the child a healthier life.

CBD has recently joined the ranks of effective anti-seizure meds. A study held in Australia and New Zealand found that CBD gel is effective against seizures, especially in children who have severe epilepsy. The study was led by professors Lynette Sadlier, a pediatric neurologist at the University of Otago, Wellington, and Ingrid Scheffer, a pediatric neurologist at the University of Melbourne. In total, 48 patients between the age of 3 and 16 years enrolled in the trials, 28 in each center.

The CBD gel was applied to the patients as a transdermal treatment, and it had some very promising results. Within the second and sixth months of being treated, the number of focal impaired awareness and convulsive seizures suffered by the children reduced by 58%. By the fifth month of treatment, 63% of the patients were reporting a 50% reduction in the number of seizures they were experiencing.

The gel was especially effective against Development and Epileptic Encephalopathies, which are among the hardest epilepsies to manage and treat. It reduced the number of epileptic seizures the children experienced, led to an overall improvement in behavioral and cognitive symptoms, and it was generally well tolerated.

According to Professor Sadlier, CBD gels offer new hope for children and adolescents who experience epileptic seizures, especially those who have few effective treatment options.  The CBD gel significantly increases the chances that kids with severe epilepsy will get to go to school regularly and live healthy, less stressful life.

Living with epilepsy is not a bed of roses. True, there are a lot of ingestible medicines that help, but when have kids ever enjoyed taking medication? Children with disabilities especially have trouble taking drugs orally. This makes CBD gel even more suitable for children. Not only does it have very promising results, but it’s the first anti-seizure medicine that won’t have to be taken orally. Administering this treatment to kids will be simpler, faster, and much easier on them.

Industry watchers believe that CBD companies like SinglePoint Inc. (OTCQB: SING) and Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) are happy about the results of the Australian study since it means more epileptic kids will get a chance at a normal life.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office